Bussières Jean-François, Tanguay Cynthia, Touzin Karine, Langlois Eric, Lefebvre Michel
, BPharm, MSc, MBA, FCSHP, is Head of the Pharmacy Department and Pharmacy Practice Research Unit, Centre hospitalier universitaire Sainte-Justine, and Professor in the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.
Can J Hosp Pharm. 2012 Nov;65(6):428-35. doi: 10.4212/cjhp.v65i6.1190.
Since publication of the US National Institute for Occupational Safety and Health alert on hazardous drugs in 2004, many health care organizations have reviewed their procedures for handling hazardous drugs. Occupational exposure may occur when handling, compounding, or administering a drug considered to be hazardous, at any stage from storage to waste management.
To describe environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in pharmacy and patient care areas of Quebec hospitals.
Sixty-eight hospitals were invited to participate. At each hospital, 12 prespecified measurement sites (6 each within pharmacy and patient care areas) were sampled once (midweek, end of day). The samples were analyzed by ultra-performance liquid chromatography tandem mass spectrometry to determine the presence of the 3 drugs. The limits of detection (LODs) were 0.0015 ng/cm(2) for cyclophosphamide, 0.0012 ng/cm(2) for ifosfamide, and 0.0060 ng/cm(2) for methotrexate.
Twenty-five (37%) of the hospitals agreed to participate. Samples from sites other than the 12 prespecified sites were excluded. Overall, 259 valid samples were collected between April 2008 and January 2010 (147 samples from pharmacy areas in 25 hospitals and 112 samples from patient care areas in 24 hospitals). No hospital was using a closed-system drug transfer device at the time of the study. The median (minimum, maximum) number of sites per hospital with at least 1 positive sample for at least 1 of the 3 hazardous drugs was 6 (1, 12). A total of 135 (52%) samples were positive for cyclophosphamide, 53 (20%) for ifosfamide, and 7 (3%) for methotrexate. The median (minimum, maximum) concentration in positive samples was 0.0035 ng/cm(2) (below LOD, 28 ng/cm(2)) for cyclophosphamide, below LOD (below LOD, 8.6 ng/cm(2)) for ifosfamide, and below LOD (below LOD, 0.58 ng/cm(2)) for methotrexate.
The levels of environmental contamination with 3 hazardous drugs in this multicentre study were similar to or below those in most published studies. Periodic measurement of surface contamination is necessary to ensure that current practices limit occupational exposure to hazardous drugs.
自美国国家职业安全与健康研究所于2004年发布关于危险药物的警报以来,许多医疗保健机构已对其处理危险药物的程序进行了审查。在从储存到废物管理的任何阶段,处理、配制或施用被认为是危险的药物时都可能发生职业暴露。
描述魁北克医院药房和患者护理区域中环磷酰胺、异环磷酰胺和甲氨蝶呤的环境污染情况。
邀请了68家医院参与。在每家医院,对12个预先指定的测量点(药房和患者护理区域各6个)进行一次采样(周三,工作日结束时)。通过超高效液相色谱串联质谱法对样本进行分析,以确定这3种药物的存在情况。环磷酰胺的检测限为0.0015 ng/cm²,异环磷酰胺为0.0012 ng/cm²,甲氨蝶呤为0.0060 ng/cm²。
25家(37%)医院同意参与。来自12个预先指定地点以外的样本被排除。总体而言,在2008年4月至2010年1月期间共收集了259份有效样本(25家医院药房区域的147份样本和24家医院患者护理区域的112份样本)。在研究期间,没有医院使用封闭系统药物转移装置。每家医院至少有1个样本对至少1种3种危险药物呈阳性的地点中位数(最小值,最大值)为6(1,12)。共有135份(52%)样本中环磷酰胺呈阳性,53份(20%)异环磷酰胺呈阳性,7份(3%)甲氨蝶呤呈阳性。阳性样本中的浓度中位数(最小值,最大值)为:环磷酰胺0.0035 ng/cm²(低于检测限,28 ng/cm²),异环磷酰胺低于检测限(低于检测限,8.6 ng/cm²),甲氨蝶呤低于检测限(低于检测限,0.58 ng/cm²)。
在这项多中心研究中,3种危险药物的环境污染水平与大多数已发表研究中的水平相似或更低。定期测量表面污染对于确保当前做法限制职业接触危险药物是必要的。